ERBB2 and breast cancer: Further, to investigate the role of SR-BI in a triple-negative (lacking the estrogen receptor (ER), progesterone receptor (PR), and Her2) basal B subtype breast cancer cell line, we determined the effect of knocking down SR-BI on the proliferation of MDA-MB-231 cells.